Fjarde AP Fonden Fourth Swedish National Pension Fund Has $9.15 Million Stake in IDEXX Laboratories, Inc. $IDXX

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in IDEXX Laboratories by 3.8%, owning a total of 21,792 shares worth approximately $9.15 million as of the latest SEC filing.
• Several institutional investors, including GAMMA Investing LLC, increased their stakes significantly, with GAMMA’s stake jumping by 59,810.7%, amounting to over $3.85 billion in holdings.
• IDEXX Laboratories reported earnings of $3.63 per share for the last quarter, exceeding analysts' expectations, with revenue reaching $1.11 billion, which is a 10.6% increase year-over-year.

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,792 shares of the company's stock after purchasing an additional 800 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in IDEXX Laboratories were worth $9,152,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. GAMMA Investing LLC raised its stake in shares of IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock valued at $3,856,950,000 after purchasing an additional 916,898 shares during the period. Nuveen LLC acquired a new stake in shares of IDEXX Laboratories in the 1st quarter valued at about $179,784,000. Principal Financial Group Inc. raised its stake in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after purchasing an additional 414,802 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $156,412,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of IDEXX Laboratories by 221.3% in the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock valued at $182,459,000 after acquiring an additional 303,966 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded up $3.14 during midday trading on Wednesday, reaching $639.85. 525,226 shares of the company's stock were exchanged, compared to its average volume of 845,060. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The firm has a market cap of $51.19 billion, a price-to-earnings ratio of 53.28, a P/E/G ratio of 4.12 and a beta of 1.49. The stock's 50-day simple moving average is $565.36 and its 200 day simple moving average is $491.59.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a report on Monday, August 4th. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. BTIG Research raised their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Morgan Stanley raised their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $649.44.

Insider Activity

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the completion of the sale, the chief executive officer directly owned 83,311 shares in the company, valued at $52,650,885.78. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the sale, the executive vice president owned 6,156 shares of the company's stock, valued at $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,870 shares of company stock valued at $32,877,757. Company insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.